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Loss of placental thrombomodulin in
oocyte donation pregnancies
Manon Bos, B.Sc.,a Hans J. Baelde, Ph.D.,a Jan A. Bruijn, M.D., Ph.D.,a KittyW. M. Bloemenkamp, M.D., Ph.D.,b
Marie-Louise P. van der Hoorn, M.D., Ph.D.,c and Rosanne J. Turner, B.Sc.a
a Department of Pathology, Leiden University Medical Centre, Leiden; b Department of Obstetrics, University Medical
Center Utrecht, Wilhelmina Children's Hospital, Utrecht; and c Department of Obstetrics, Leiden University Medical
Centre, Leiden, the NetherlandsObjective: To investigate whether thrombomodulin dysregulation is involved in the development of preeclampsia after oocyte dona-
tion (OD). Women who become pregnant after OD are prone to develop preeclampsia, a syndrome characterized by an aberrant immu-
nologic response, hypercoagulability, and endothelial dysfunction. A mediator of inflammation and coagulation is thrombomodulin,
which has a possible role to play in this syndrome.
Design: Case-control study.
Setting: Not applicable.
Patient(s): Placentas from 82womenwith an uncomplicated pregnancy (48 naturally conceived, 21 IVF, and 33 OD pregnancies) and 9
women with an OD pregnancy complicated by preeclampsia have been studied.
Intervention(s): None.
Main Outcome Measure(s): Abundances of thrombomodulin protein and vitamin D receptor (VDR) were determined using immuno-
histochemistry; mRNA expression was determined using quantitative polymerase chain reaction.
Result(s): Placental thrombomodulin protein abundance was lower in OD pregnancies (diffuse pattern in 45%) than in controls (diffuse
pattern in 96%). Placental thrombomodulin mRNA expression was lower in OD pregnancies complicated by preeclampsia (0.72 0.47)
compared with in uncomplicated OD pregnancies (0.43  0.18). Thrombomodulin expression correlated with inflammation and coag-
ulation. VDR expression was decreased in OD pregnancies complicated by preeclampsia and was correlated with thrombomodulin
mRNA.
Conclusion(s): Pregnancies conceived through OD lose placental thrombomodulin expression. This loss is associated with an increased
coagulation and inflammation and indicates that endothelial protection is diminished in OD pregnancies, which might be an explana-
tion for the increased risk for preeclampsia. Vitamin D metabolism is dysregulated in OD pregnancies and might be a target for therapy.
(Fertil Steril 2017;107:119–29. 2016 by American Society for Reproductive Medicine.)
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16110-fertility-and-sterility/posts/12484-22883O ocyte donation (OD) is a tech-nique that enables womenwith diminished ovarian
reserve to conceive. Pregnancy is a
challenging state for the mother's im-
mune system, where a controlled envi-
ronment with a regulated immune
response to the semiallogeneic fetus
has to be established. After OD, the
fetus is completely allogeneic; this
even more challenging environment
for the immune system is presumed to
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ter OD (1, 2). These complications can
be explained, in large part, by the
increased prevalence of pregnancy-
induced hypertension and preeclamp-
sia (3–8).
Preeclampsia, a hypertensive disor-
der during pregnancy, is a leading
cause of maternal and neonatal
morbidity and mortality worldwide
(9). The pathophysiology of preeclamp-
sia is not fully understood, but the syn-
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Medicine, Published by Elsevier Inc.placental development and subsequent
shedding of syncytial trophoblast.
This results in the release of antiangio-
genic factors such as soluble Flt-1,
which binds to vascular endothelial
growth factor in the circulation (10).
These factors contribute to a maternal
intravascular systemic inflammatory
response, leading to generalized endo-
thelial dysfunction, enhanced leuko-
cyte and complement activation, and
coagulation (10).
The role of the placenta in the
pathogenesis of preeclampsia in OD
pregnancies is presumed to be different
from that in preeclampsia in naturally
conceived pregnancies (11–13).
Although these patients are subject to
an increased risk of preeclampsia
because of older age (9), it is also119
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONknown that OD is an independent risk factor for hypertensive
complications of pregnancy (14, 15). Furthermore, the clinical
presentation of these patients is different from patients with
preeclampsia after a naturally conceived pregnancy: growth
restriction after OD pregnancies complicated by
preeclampsia is less severe (6, 12, 16, 17). Moreover, the
pathophysiology of preeclampsia after naturally conceived
pregnancies seems to be of a more vascular origin (10),
whereas preeclampsia after OD presumably has a more
immunological origin (1, 11, 12, 18).
In women with preeclampsia in naturally conceived preg-
nancies, serum levels of the breakdown product of thrombo-
modulin are higher in comparison with uncomplicated
naturally conceived pregnancies (19), and placental thrombo-
modulin protein andmRNA expression in naturally conceived
pregnancies is decreased (20). Thrombomodulin is a protein
essential for the maintenance of endothelium; it inhibits in-
flammatory pathways and apoptotic pathways in endothelial
cells, and it inhibits coagulation (21). The pathways through
which thrombomodulin is regulated in the placenta are
currently not precisely known, but the angiogenic imbalance,
as seen in preeclampsia, has been shown to decrease thrombo-
modulin expression (20). Another possible regulator of
placental thrombomodulin is vitamin D; decreased vitamin
D levels are associated with an increased incidence of pre-
eclampsia (22), and vitamin D increases thrombomodulin
expression in endothelial aorta cells (23).
Despite the fact that the placenta is presumed to have a
different role in the pathophysiology of preeclampsia after
OD pregnancies and naturally conceived pregnancies; the
placental thrombomodulin expression might be alterd in OD
pregnancies complicated by preeclampsia as well. In both
naturally conceived and OD pregnancies, preeclampsia is
characterized by endothelial dysfunction, inflammation,
and hypercoagulability (12). Therefore, our objectives are to
investigate placental thrombomodulin expression, down-
stream effects of thrombomodulin, and the regulation of
thrombomodulin in women with preeclampsia after OD and
in women with uncomplicated pregnancies that were either
naturally conceived (20), induced by IVF, or induced by OD,
as control subjects. We hypothesize that thrombomodulin
expression is altered in OD pregnancies complicated by
preeclampsia.MATERIALS AND METHODS
Patients Who Underwent OD and Control Groups
A case-control study with 56 placentas fromwomen pregnant
after OD in the Leiden University Medical Centre (LUMC) and
teaching hospitals in the region between 2004 and 2013 was
performed; 40 placentas were from pregnancies without hy-
pertensive complications, and 16 placentas were from women
with preeclampsia according to International Society for the
Study of Hypertension in Pregnancy (ISSHP) guidelines
(24). Patients who had an OD with at least information on
maternal age, gestational age, birth weight, highest diastolic
blood pressure, and available paraffin-embedded placenta
samples were included. Twenty-eight uncomplicated natu-
rally conceived pregnancies and 21 IVF-induced pregnancies120were selected from available patients as controls. Using IVF
pregnancies and naturally conceived pregnancies as controls
for OD pregnancies has been described before in comparable
studies (12, 18). Controls were selected on the basis of mode
of delivery, because mode of delivery has a broad impact on
the placenta and influences gene expression (25). No other
selection criteria were used.
Small for gestational age was defined as birth weight
below the 10th percentile for gestational age according to the
Dutch reference curves for birth weight by gestational age (26).
Patient characteristics were obtained from the medical re-
cords. From all placentas, paraffin-embedded samples were
available for immunohistochemical staining. Frozen tissue,
which was used for mRNA analysis, was available for 36 un-
complicated OD placentas, 16 placentas from an OD preg-
nancy complicated by preeclampsia, and 10 placentas from
an uncomplicated naturally conceived pregnancy. As previ-
ously described, the placentas of twins and triplets were
treated as individual samples, since placental pathology can
be different in twins. Informed consent was obtained from
all patients. This study was approved by the ethics committee
of LUMC (P13.084).Thrombomodulin and Maternal Age
Placentas from an additional group of older women (n ¼ 20;
maternal age>37) with an uncomplicated naturally conceived
pregnancy were included to investigate the effect of maternal
age on placental thrombomodulin protein expression.Histochemical Staining
Histological phosphotungistic acid-hematoxylin (PTAH)
staining was performed to investigate the presence of fibrin
depositions. Sections were incubated in 0.25% potassium per-
manganate for 15 minutes followed by 5% oxalic acid for
5 minutes. Sections were then incubated in PTAH for 24 hours
at room temperature.Immunohistochemistry
Immunohistochemical staining was performed to investigate
the placental protein abundance of thrombomodulin and the
vitamin D receptor (VDR). We choose to determine placental
VDR expression since decreased placental VDR expression
has been described as a proper measure for disturbances in
vitamin D signaling before (27, 28).
Sections were deparaffinized, and antigen retrieval was
performed. Sections were incubated with anti-
thrombomodulin mouse monoclonal antibody (1:200; Leica
Biosystems) or an anti-VDR mouse monoclonal antibody
(1:1,500) for 1 hour at room temperature. Binding of the pri-
mary antibody was visualized with a PO-labeled anti-mouse
polymer (DAKO) and diaminobenzidine as a chromogen.Scoring of Staining Patterns
Slides were scored by two observers blinded with respect to
cases and control groups. Twenty percent of cases were scored
differently between observers, and for those, consensus wasVOL. 107 NO. 1 / JANUARY 2017
Fertility and Sterility®obtained during a consensus meeting. Thrombomodulin pro-
tein abundance at the surface of viable syncytiotrophoblast
was scored semiquantitatively as absent (present on <10%
of viable syncytiotrophoblast), focal (present on 10%–50% of
viable syncytiotrophoblast), or overall (present on >50%
of viable syncytiotrophoblast) as described elsewhere (20).
Viability of syncytiotrophoblast was confirmed using
hematoxylin-eosin staining. The presence of fibrin depositions
on the villi was scored similarly.
VDR abundance at the surface of syncytiotrophoblast was
scored semiquantitatively as overall (>90% of syncytiotropho-
blast positive for VDR), decreased (90%–50%of syncytiotropho-
blast positive VDR), and absent (<50% of syncytiotrophoblast
positive for VDR).Quantitative Polymerase Chain Reaction (PCR)
Quantitative PCR was performed to quantify placental mRNA
expression of thrombomodulin, VDR, intercellular adhesion
molecule-1, tumor necrosis factor-alpha, factor VIII, tissue
factor, vascular endothelial growth factor, and soluble FLT-1.
Primer sequences can be found in Supplemental Table 1. RNA
isolation was performed with TRIzol (Lifetechnologies). Syn-
thesis of cDNA was performed with AMV reverse transcrip-
tase (Roche), and SYBR green quantitative PCR was
performed according to the manufacturer's protocol (Bio-
Rad Laboratories). Expression was measured by the compara-
tive threshold cycle method and normalized to expression of
housekeeping genes hypoxanthine phosphoribosyltransfer-
ase and GAPDH. A melting curve analysis was performed to
verify the specificity of amplification.Cell Culture Experiments
Cell culture experiments were performed to investigate
placental thrombomodulin regulation through vitamin D
signaling. The human choriocarcinoma cell line BeWo
(CCL-98, ATCC) was cultured in RPMI medium supplemented
with 10% fetal calf serum. Short tandem repeat analysis with
GenePrint (Promega) confirmed the identity of the cells. Cells
were used within 25 passages.
Forskolin (50 mM, dissolved in dimethyl sulfoxide 0.1%;
Sigma-Aldrich) was used to stimulate VDR expression (29).
Vitamin D (dissolved in ethanol 1%, Sigma-Aldrich) was added
to the medium with a final concentration of 100 nM (29).
Cells were cultured for 24 hours, and then forskolin alone
or forskolin with 1,25-di-hydroxyl-vitamin D was added to
refreshed medium (29). Cells were cultured for 48 hours before
mRNA was isolated (29). Normalized mRNA expression of
thrombomodulin and VDR was measured. Experiments were
repeated 4 times.Statistical Analysis
For statistical analyses, placentas from OD pregnancies
complicated by preeclampsia were compared with placentas
from uncomplicated OD pregnancies. Placentas from uncom-
plicated OD pregnancies were compared with placentas from
uncomplicated naturally conceived and uncomplicated IVF-
induced pregnancies.VOL. 107 NO. 1 / JANUARY 2017Factors considered potential confounders were maternal
age at pregnancy, body mass index (BMI), smoking, gravidity,
parity, and twin or triplet pregnancy. Continuous data were
compared between groups using the independent t-test for
normally distributed data or a Mann-Whitney U-test for
skewed distributions. Discontinuous data were analyzed
with the c2-test of Fisher's exact test.
Correlations between thrombomodulin mRNA and other
mRNA levels or clinical parameters were determined with
the Spearman's rho test or Pearson test. P< .05 was consid-
ered statistically significant. Analyses were performed with
the IBM SPSS statistics software package (ver. 21; IBM).RESULTS
Patient Characteristics
Patient characteristics can be found in Table 1. The mean
age of women who had a naturally conceived pregnancy
(33.7 years) or a pregnancy after IVF (35.0 years) was signif-
icantly lower than the mean age of women with an uncom-
plicated OD pregnancy (38.5 years; P< .05 for both). The
average age of women with OD pregnancies complicated
by preeclampsia was 42.9 years; this was significantly
higher compared with women with uncomplicated OD preg-
nancies (P< .05). The mean BMI of women with a naturally
conceived pregnancy was significantly higher than the
mean BMI of women with an uncomplicated OD pregnancy
(respectively, 25.81 and 21.37; P< .05 for both). The mean
BMI of women with preeclampsia during OD pregnancies
was higher than the mean BMI of women with uncompli-
cated OD pregnancies (P¼ .044). Medical histories from pre-
vious pregnancies were available for all control cases and
for 46 out of 56 OD pregnancies. In none of our cases was
a history of hypertension or preeclampsia reported in the
medical records. Furthermore, none of the patients with an
OD-induced pregnancy had diabetes mellitus, gestational
diabetes, or disturbances in coagulation according to the
medical records. Three women with an uncomplicated OD
pregnancy had proteinuria, and five had a diastolic blood
pressure > 85 mmHg. Nevertheless, none of these women
fulfilled the ISSHP criteria (24) for the diagnosis of pre-
eclampsia nor were they treated for these symptoms.Pregnancy Characteristics
Mean gestational age was significantly lower in children born
after OD pregnancies complicated by preeclampsia (P< .001).
In OD pregnancies, more twins and triplets were seen
compared with in naturally conceived pregnancies (P< .01),
and women pregnant with twins or triplets more often had
preeclampsia (P< .01).Fetal Characteristics
The mean birth weight of children was lower in IVF pregnan-
cies compared with in naturally conceived pregnancies and
compared with in OD pregnancies complicated by preeclamp-
sia (P< .001). When corrected for gestational age, these differ-
ences were no longer significant.121
TABLE 1
Patient characteristics.
NC (n [ 28) IVF (n [ 21) OD (n [ 33) OD PE (n [ 9)
Maternal characteristics
Maternal age (y), mean (SD) 33.7 (4.0) 35.0 (3.9) 38.5 (5.8)a,b 42.9 (4.7)c
Maternal BMI (kg/m2), mean (SD) 25.81 (4.9) 24.65 (5.2) 21.37 (1.9)a 24.21 (0.9)c
Smoking (%)
Yes 1 (3.6) 2 (10) 1 (6.7) 1 (16.7)
No 27 (96.4) 18 (90) 14 (93.3) 5 (83.3)
Gravidity, mean (range) 2.9 (1–7) 2.2 (1–5)a 2.1 (1–7)a 2.1 (1–5)
Parity, mean (range) 1.4 (0–5) 0.5 (0–2)a 0.4 (0–2)a 0.2 (0–1)
Highest diastole, mmHg (SD) 75 (70–80) 80 (65–95)a 80 (60–90)a 99 (85–115)c
Proteinuria, n (%)
Yes 0 (0) 1 (5.6) 3 (23.1) 9 (100)
No 28 (100) 17 (94.4) 10 (76.9)a 0 (0)c
Prior history of hypertension or preeclampsia, n (%)
Yes 0 (0) 0 (0) 0 (0) 0 (0)
No 28 (100) 21 (100) 25 (100) 7 (100)
Pregnancy characteristics
Gestational age at delivery, wk þ
d (SD [d])
39 þ 4 (9) 38 þ 5 (17) 39 þ 2 (15) 34 þ 2 (21)c
Term (%)
A term 28 (100) 15 (78.5) 30 (93.8) 2 (22.2)
Preterm 0 (0) 4 (21.5)a 2 (6.2) 7 (77.8)c
Mode of delivery, n (%)
Caesarean section 16 (57.1) 9 (45) 17 (54.8) 6 (66.7)
Vaginal delivery 12 (42.9) 11 (55) 14 (45.2) 3 (33.3)
Twin or triplet, n (%)
Yes 0 (0) 1 (5) 7 (21.2) 6 (66.7)
No 28 (100) 19 (95) 26 (78.8)a 3 (33.3)c
Fetal characteristics n ¼ 28 n ¼ 21 n ¼ 40 n ¼ 16
Sex of child, n (%)
Male 12 (42.9) 10 (47.6) 20 (54.1) 9 (56.3)
Female 16 (57.1) 11 (52.4) 17 (45.9) 7 (43.9)
Birth weight, g (SD) 3,597 (435) 3,113 (701)a 3,297 (717) 1,952 (660)c
Small for gestational age, n (%)
Yes 2 (7.1) 3 (14.3) 3 (8.1) 0 (0)
No 26 (92.9) 18 (85.7) 34 (91.9) 14 (100)
Placenta weight, g (SD) 638 (140) 611 (149) 698 (204) 863 (238)
Note: NC ¼ naturally conceived; OD PE ¼ OD pregnancies complicated by preeclampsia.
a P< .05 compared with uncomplicated NC pregnancies.
b P< .05 compared with uncomplicated IVF pregnancies.
c P< .05 compared with uncomplicated OD pregnancies.
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Placental thrombomodulin staining was observed in three
distinct patterns; representative examples of these patterns
are depicted in Figure 1A–1C. Syncytiotrophoblast thrombo-
modulin protein abundance was decreased more often after
uncomplicated OD pregnancies and after OD pregnancies
complicated by preeclampsia compared with pregnancies
conceived through IVF and naturally conceived pregnancies
(P< .001; Fig. 1D).Thrombomodulin Protein Expression in Older
Women
Since the maternal age of women who had an uncomplicated
OD pregnancy was significantly higher than that of women
who had a naturally conceived pregnancy or a pregnancy af-
ter IVF, we included an additional group of women>37 years
who had an uncomplicated naturally conceived pregnancy to
study the effect of maternal age on placental thrombomodu-
lin expression. The mean maternal age of these women was12239.4 years; this was significantly higher compared with
women who had an uncomplicated naturally conceived preg-
nancy; characteristics of this additional group are depicted in
Supplemental Table 2. Placental thrombomodulin expression
was diffuse in 19 out of 20 older women; this was similar as
the placental thrombomodulin abundance in the group of un-
complicated naturally conceived control pregnancies in
younger women.Thrombomodulin mRNA Expression
Placental thrombomodulinmRNA expression was decreased in
women with preeclampsia after OD, compared with in uncom-
plicated OD pregnancies (P< .001, Fig. 1E). Placental thrombo-
modulin mRNA expression was similar in naturally conceived
pregnancies and uncomplicated OD pregnancies. Thrombomo-
dulin mRNA expression was slightly higher in samples with an
overall thrombomodulin protein staining pattern (mean ¼
0.5415; SD ¼ 0.1315) compared with samples with a focal or
absent staining pattern (mean ¼ 0.3891; SD ¼ 0.1850) in OD
pregnancies complicated by preeclampsia (P¼ .138).VOL. 107 NO. 1 / JANUARY 2017
FIGURE 1
Placental thrombomodulin expression. (A) Representative example of an absent (<10% of viable syncytiotrophoblast) placental thrombomodulin
protein expression pattern. (B) Representative example of a focal (10%–50% of viable syncytiotrophoblast) placental thrombomodulin protein
expression pattern. (C) Representative example of an overall (>50% of viable syncytiotrophoblast) placental thrombomodulin protein
expression pattern. (D) Distribution of placental thrombomodulin protein abundance patterns in women with an OD pregnancy complicated by
preeclampsia and control groups (P<.001 for overall c2 testing). (E) Relative normalized placental thrombomodulin mRNA expression in case
and control groups (*P<.05, Mann-Whitney U-test). (F) Correlation of thrombomodulin mRNA expression and maternal age in OD pregnancies
complicated by preeclampsia (r ¼ 0.758, P<.001, Pearson's correlation test). (G) Correlation of thrombomodulin mRNA expression and
maternal age in uncomplicated OD pregnancies (P>.05, Pearson's correlation test). NC ¼ naturally conceived; OD PE ¼ OD pregnancies
complicated by preeclampsia; NS ¼ not significant.
Bos. Thrombomodulin in oocyte donation. Fertil Steril 2016.
Fertility and Sterility®Thrombomodulin mRNA correlated inversely with
maternal age in the preeclampsia OD group (r ¼ 0.758,
P¼ .001; Fig. 1F). This correlation was not present in uncom-
plicated OD pregnancies (Fig. 1G). Thrombomodulin mRNA
levels were not associated with fetal characteristics nor pa-
tient characteristics. Furthermore, thrombomodulin mRNA
levels were similar in multiplets and singletons in uncompli-
cated OD pregnancies and OD pregnancies complicated by
preeclampsia (Supplemental Fig. 1).VOL. 107 NO. 1 / JANUARY 2017Downstream Effects of Thrombomodulin:
Coagulation
Fibrin depositions were evenly distributed over all groups
(Fig. 2A). Increasing thrombomodulin protein abundance
was associated with decreasing presence of fibrin deposits
in women with OD pregnancies complicated by preeclampsia
(P¼ .019; Fig. 2B). This association was not present between
thrombomodulin mRNA levels and fibrin deposits.123
FIGURE 2
Downstream effects of thrombomodulin: coagulation and inflammation. (A) Presence of fibrin deposits as detected with histological PTAH staining
in placentas from OD pregnancies complicated by preeclampsia and control pregnancies (naturally conceived, IVF and OD; P>.05 with overall c2
testing). (B) The association between placental thrombomodulin expression pattern and the amount of fibrin deposits in OD pregnancies
complicated by preeclampsia (P¼.019, with overall c2 testing). (C) Relative normalized tissue factor and factor VIII mRNA expression in OD
pregnancies complicated by preeclampsia and control groups (*P<.05, Mann-Whitney U-test). (D) Correlation of factor VIII and
thrombomodulin mRNA expression in the uncomplicated OD control group (r ¼ 0.552, P<.001). (E) Correlation of normalized tissue factor
mRNA and thrombomodulin mRNA expression in the uncomplicated OD control group (r ¼ 0.460, P¼.009). (F) Correlation of normalized
tissue factor mRNA and thrombomodulin mRNA expression in OD pregnancies complicated by preeclampsia (r ¼ 0.521, P¼.046).
(Continued on next page)
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FIGURE 2 Continued
(G) Relative normalized tumor necrosis factor-alpha and intercellular adhesion molecule-1 mRNA expression in placentas of women with
preeclampsia after OD and control groups (**P<.001; Mann-Whitney U-test). (H) Correlation of intercellular adhesion molecule 1 and
thrombomodulin mRNA expression in uncomplicated OD control pregnancies r ¼ 0.739, P<.001; Pearson's correlation test). ICAM-1 ¼
intercellular adhesion molecule-1; NC ¼ naturally conceived; OD PE ¼ OD pregnancies complicated by preeclampsia; TNFa ¼ tumor necrosis
factor-alpha; NS ¼ not significant.
Bos. Thrombomodulin in oocyte donation. Fertil Steril 2016.
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was slightly lower in uncomplicated OD pregnancies compared
with in naturally conceived pregnancies and were lower in OD
pregnancies complicated by preeclampsia compared with
naturally conceived pregnancies (P< .05 for both; Fig. 2C).
However, placental mRNA levels of tissue factor and factor
VIII were not different between OD pregnancies complicated
by preeclampsia and uncomplicated OD pregnancies.
Placental thrombomodulin mRNA expression and factor
VIII mRNA expression were correlated in uncomplicated OD
pregnancies (r¼ 0.552, P< .001; Fig. 2D). Placental thrombo-
modulin mRNA expression correlated with tissue factor
mRNA expression in uncomplicated OD pregnancies (r ¼
0.460, P¼ .009; Fig. 2E) and OD pregnancies complicated by
preeclampsia (r ¼ 0.521, P¼ .046; Fig. 2F).Downstream Effects of Thrombomodulin:
Inflammation
Placental tumor necrosis factor-alpha and intercellular adhe-
sion molecule-1 mRNA expression were similar in uncompli-
cated OD pregnancies and naturally conceived pregnancies.
Remarkably, tumor necrosis factor-alpha and intercellular
adhesion molecule-1 mRNA levels were lower in OD pregnan-
cies complicated by preeclampsia compared with in uncompli-
cated OD pregnancies (P< .001 for both; Fig. 2G). Placental
thrombomodulin mRNA expression correlated positively with
intercellular adhesionmolecule-1mRNA expression in uncom-
plicated OD pregnancies (r ¼ 0.739, P< .001; Fig. 2H).Regulation of Thrombomodulin: Angiogenic
Factors
Placental vascular endothelial growth factor mRNA expres-
sion was higher in uncomplicated naturally conceived preg-
nancies compared with in uncomplicated OD pregnanciesVOL. 107 NO. 1 / JANUARY 2017and OD pregnancies complicated by preeclampsia (P¼ .038
and P¼ .013; Supplemental Fig. 2). Placental soluble Flt-1
mRNA expression was higher in complicated OD pregnancies
compared with in uncomplicated OD pregnancies (P¼ .006;
Supplemental Fig. 2). Thrombomodulin mRNA expression
and protein abundance were not associated with vascular
endothelial growth factor or soluble Flt-1 mRNA expression.Regulation of Thrombomodulin: Vitamin D
Placental VDR protein abundance was observed in three distinct
patterns; representative examples of these patterns can be found
in Figure 3A–3C. VDR abundance differed between groups, with
ODpregnancies complicated bypreeclampsia tending to be asso-
ciated with decreased VDR abundance (P< .05; Fig. 3D). No sea-
sonal changes of VDR abundance were observed in this cohort.
Placental VDR mRNA expression was lower in OD preg-
nancies complicated by preeclampsia compared with in natu-
rally conceived pregnancies (P¼ .016; Fig. 3E). Placental
thrombomodulin mRNA expression was positively correlated
with placental VDR mRNA expression in uncomplicated OD
pregnancies (r ¼ 0.704, P< .001; Fig. 3F) and OD pregnancies
complicated by preeclampsia (r ¼ 0.582, P¼ .029; Fig. 3G).
Placental VDR mRNA expression was significantly higher in
women pregnant after OD when the child was born in the
spring compared with children born in the autumn (P< .05).
Other associations with seasonality and VDR mRNA expres-
sion levels could not be found (Supplemental Fig. 3).In Vitro Experiments on Vitamin D Signaling and
Thrombomodulin
Adding forskolin to cell culture medium led to increased VDR
mRNA expression compared with cells cultured in control
medium, as described elsewhere (29). Cells cultured with
50 mM forskolin and 100 nM vitamin D expressed higher125
FIGURE 3
Regulation of thrombomodulin: vitamin D. (A) Representative example of a low (<50%) placental VDR expression pattern. (B) Representative
example of a decreased/focal (50%–90%) placental VDR expression pattern. (C) Representative example of a diffuse (>90%) placental VDR
expression pattern. (D) Placental VDR protein abundance patterns in women with an OD pregnancy complicated by preeclampsia and control
groups (*P<.05, c2 testing). (E) Relative normalized placental VDR mRNA expression in OD pregnancies complicated by preeclampsia and
control groups (*P<.05; Mann-Whitney U-test). (F) Correlation of VDR mRNA expression and thrombomodulin mRNA expression in
uncomplicated OD pregnancies (r ¼ 0.708, P<.001; Pearson's correlation test). (G) Correlation of VDR mRNA expression and thrombomodulin
mRNA expression in OD pregnancies complicated by preeclampsia (r ¼ 0.582, P¼.029; Pearson's correlation test). (H) Relative normalized
thrombomodulin mRNA expression in BeWo cells cultured with forskolin and vitamin D and in cells cultured with control medium. NC ¼
naturally conceived; OD PE ¼ OD pregnancies complicated by preeclampsia.
Bos. Thrombomodulin in oocyte donation. Fertil Steril 2016.
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cultured with control medium (Fig. 3H).DISCUSSION
Compelling evidence indicates that pregnancies after OD are
subject to a vast risk of preeclampsia (1–8), but the
underlying pathophysiology of this phenomenon remains
uncertain. Similar to what has been described in naturally
conceived pregnancies complicated by preeclampsia (20), we
show that placental thrombomodulin mRNA expression is
decreased in OD pregnancies complicated by preeclampsia.126Furthermore, thrombomodulin protein abundance is
decreased in uncomplicated OD pregnancies and OD
pregnancies complicated by preeclampsia; this could indicate
that loss of thrombomodulin, due to loss of endothelial
protection, plays a role in the development of more
pregnancy complications in OD pregnancies. Decreased
thrombomodulin expression is associated with changes in
coagulation pathways and inflammatory pathways.
Furthermore, this study demonstrates that disturbances in the
vitamin D metabolism possibly contribute to placental
thrombomodulin loss during OD pregnancies. We found that
decreased VDR expression is associated with loss ofVOL. 107 NO. 1 / JANUARY 2017
Fertility and Sterility®thrombomodulin in OD pregnancies and that vitamin D
increases thrombomodulin expression in vitro.
Loss of placental thrombomodulin in OD pregnancies calls
into question whether thrombomodulin loss in OD pregnancies
lies in the causal pathway of the development of preeclampsia
or whether this loss is merely a result of the OD and subsequent
immunological disturbances. Thrombomodulin loss may be
caused by specific maternal characteristics typical for endothe-
lial dysfunction. For example, we previously showed that
thrombomodulin mRNA expression correlated significantly
withmaternal BMI and diastolic blood pressure in preeclampsia
in naturally conceived pregnancies (20). Furthermore, in this
study we showed that maternal age correlated significantly
with thrombomodulin mRNA in OD pregnancies complicated
by preeclampsia. Because of this correlation, and because
increasing age is associated with loss of endothelial protection,
the older age of the OD group could explain the thrombomodu-
lin loss seen in this group. However, placental thrombomodulin
protein expression was not decreased in older women who had
anuncomplicatednaturally conceived pregnancy.Also, no cor-
relations between thrombomodulin expression and maternal
characteristics such as BMI or hypertension were present.
Therefore, it seems less likely that loss of placental thrombomo-
dulin is part of the causal pathway of the development of pre-
eclampsia after OD. Logically, thrombomodulin loss could be
a result of OD, since thrombomodulin can be downregulated
by inflammatory factors, such as matrix metalloproteinases
and tumor necrosis factor-alpha (21). An OD pregnancy is a
challenging state for the mother's immune system; a regulated
immune response to the allogeneic fetus has to be established.
OD pregnancies are characterized by more human leukocyte
antigen (HLA) mismatches, more T-helper cells are found in
the peripheral blood (18, 30), and the number of activated
regulatory T-cells in the parietal decidua correlates with the
number of HLA mismatches (31). Therefore, thrombomodulin
loss in uncomplicated OD pregnancies could be caused by
OD-specific immune regulation.
On the contrary, thrombomodulin exerts cytoprotective ef-
fects through activation of anti-inflammatory pathways. Im-
mune dysregulation is a distinct pathogenic pathway in
preeclampsia. Preeclampsia is associated with placental dysre-
gulation of intercellular adhesion molecule-1 and tumor ne-
crosis factor-alpha (32–34). Indeed, we found an
upregulation of tumor necrosis factor-alpha and intracellular
adhesion molecule-1 in OD pregnancies complicated by pre-
eclampsia and a significant correlation between placental
thrombomodulin and intercellular adhesion molecule-1. An
association between preeclampsia and hypercoagulation is
also well established; it is associated with mutations in the pro-
thrombin and factor V Leiden genes, and the use of the antico-
agulant drugs decreases development, mortality, and
morbidity of preeclampsia (35–37). Loss of thrombomodulin
protein abundance in OD pregnancies could result in reduced
anticoagulation and thereby contribute to symptoms of
preeclampsia. In this study, thrombomodulin protein
abundance was inversely associated with fibrin deposits in
women with an OD pregnancy complicated by preeclampsia.
Furthermore, significant correlations of mRNA expression of
tissue factor and factor VIII with thrombomodulin mRNAVOL. 107 NO. 1 / JANUARY 2017expression were found in OD pregnancies. Together these
results indicate that loss of thrombomodulin could contribute
to the pathogenesis of preeclampsia after OD through its
distinct effects on inflammation and coagulation.
In this study, lower VDR expression on the syncytiotro-
phoblast of women with OD pregnancies complicated by pre-
eclampsia compared with naturally conceived pregnancies
was found. Decreased VDR expression is known to be associ-
ated with disturbances in vitamin D signaling, subsequent
placental disorders, and growth restriction (27, 28). In our
cohort, a decrease in VDR mRNA expression was associated
with a decrease in thrombomodulin mRNA expression.
Moreover, addition of vitamin D to cell culture medium
increased thrombomodulin mRNA expression in vitro. These
results are suggestive of vitamin D as a regulator of
thrombomodulin in placental cells. Perhaps increasing
levels of thrombomodulin through increasing vitamin D
serum levels could restore syncytiotrophoblast maintenance
in OD pregnancies. Vitamin D serum levels can be increased
via vitamin D supplementation (38). Since thrombomodulin
protein expression decreases in uncomplicated OD
pregnancies, and thrombomodulin mRNA is not upregulated
in this group, loss of thrombomodulin on the
syncytiotrophoblast is not compensated by an increased
production of thrombomodulin mRNA in uncomplicated OD
pregnancies. This is suggestive for a role of a diminished
vitamin D metabolism in the development of preeclampsia
after OD. An interesting point for further research would be
to investigate the effect of maternal vitamin D status on
placental cytoprotection through thrombomodulin.
It is difficult to define a proper control group for OD preg-
nancies. Conception through assisted reproductive techniques
on its own is associated with distinct maternal characteristics
such as older age and premature ovarian failure (14) and an
increased risk of pregnancy complications due solely to OD
(15). In our cohort, uncomplicated OD pregnancies were signif-
icantly different fromuncomplicated naturally conceived preg-
nancies with respect to maternal age, maternal BMI, gravidity,
parity, and the number of twin or triplet pregnancies. However,
IVF-induced pregnancieswere only significantly different from
uncomplicated OD pregnancies regarding maternal age and
could therefore serve as a proper control group. Additionally,
placentas from older women with an uncomplicated naturally
conceived pregnancy were included to investigate the effect
of maternal age on thrombomodulin protein expression.
Thrombomodulin expression was mainly diffuse in these sam-
ples. Furthermore, no correlation was found between maternal
age and thrombomodulin mRNA in uncomplicated OD preg-
nancies. Therefore, maternal age can probably not elucidate
thrombomodulin downregulation in uncomplicated OD preg-
nancies. Multiplets occur more often in pregnancies induced
by OD and IVF compared with in naturally conceived pregnan-
cies (39, 40). This might theoretically influence
thrombomodulin expression. To our knowledge, no current
literature on the influence of multiplet pregnancies on
placental thrombomodulin expression exists. In our study,
thrombomodulin levels were similar in placentas from
singleton and multiplet pregnancies; thrombomodulin mRNA
appears not to be affected by twin pregnancy.127
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONA limitation of this study is that only nine patients are
included in the group of OD pregnancies complicated by pre-
eclampsia. In the Netherlands, anonymous and commercial
OD is not allowed (41). Hence, the number of women who
receive OD is relatively low in the Netherlands.
In summary, in this study we showed that placental
thrombomodulin protein expression is lower after uncompli-
cated OD pregnancies and OD pregnancies complicated by
preeclampsia, which might contribute to a higher susceptibil-
ity for the development of preeclampsia after OD. Thrombo-
modulin expression is associated with parameters of
inflammation and coagulation. Furthermore, downregulation
of the VDR in OD pregnancies complicated by preeclampsia
might contribute to loss of thrombomodulin on the syncytio-
trophoblast. More research is needed to understand thrombo-
modulin regulation and other pathways contributing to the
maintenance of endothelium in women with preeclampsia
to find possible targets to treat endothelial dysfunction in
women susceptible to preeclampsia. Although a very specific
patient group was studied, our results provide new insights
into the pathogenesis of preeclampsia but also set the stage
for further research into the role of endothelium in the regu-
lation of inflammation and coagulation.
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SUPPLEMENTAL FIGURE 1
Thrombomodulin mRNA expression in singletons and multiplets.
Relative normalized placental thrombomodulin mRNA expression in
uncomplicated OD pregnancies and OD pregnancies complicated
by preeclampsia (not significant, independent t-test). NS ¼ not
significant; OD PE ¼ OD pregnancies complicated by preeclampsia.
Bos. Thrombomodulin in oocyte donation. Fertil Steril 2016.
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SUPPLEMENTAL FIGURE 2
Regulation of thrombomodulin: angiogenic factors. Relative
normalized placental vascular endothelial growth factor and soluble
Flt-1 mRNA expression in OD pregnancies complicated by
preeclampsia and control groups (*P<.05, Mann-Whitney U-test).
NC ¼ naturally conceived; OD PE ¼ OD pregnancies complicated
by preeclampsia; sFlt-1 ¼ soluble Flt-1; VEGF ¼ vascular endothelial
growth factor.
Bos. Thrombomodulin in oocyte donation. Fertil Steril 2016.
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SUPPLEMENTAL FIGURE 3
Seasonality of placental VDRmRNA expression. (A) Relative placental VDRmRNA expression of children born in spring (March 21–June 20), summer
(June 21–September 20), autumn (September 21–December 20), or winter (December 21–March 20) after an uncomplicated OD pregnancy. (B)
Relative placental VDR mRNA expression of children born in spring, summer, or autumn after OD pregnancies complicated by preeclampsia.
Placental VDR mRNA expression is significantly lower in children born in autumn compared with children born in spring (*P<.05, Mann-
Whitney U-test).
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SUPPLEMENTAL TABLE 1
Primer sequences, forward (F) or reverse (R), used for quantitative
PCR.
Gene F or R Primer sequence




















Note: HPRT ¼ hypoxanthine phosphoribosyltransferase; ICAM-1 ¼ intercellular adhesion
molecule 1; sFlt-1 ¼ soluble Flt-1; TNFa ¼ tumor necrosis factor-alpha; VEGF ¼ vascular
endothelial growth factor.
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SUPPLEMENTAL TABLE 2
Patient characteristics of older age group.
Characteristic NC (n [ 28)
Older
age (n [ 20)
Maternal
Age (y), mean (SD) 33.7 (4.0) 39.4 (1.5)a
BMI (kg/m2), mean (SD) 25.81 (4.9) 25.67 (5.6)
Smoking (%)
Yes 1 (3.6) 2 (12.6)
No 27 (96.4) 14 (87.6)
Gravidity, mean (range) 2.9 (1–7) 3.6 (1–8)
Parity, mean (range) 1.4 (0–5) 1.9 (0–5)
Diastole (mmHg), highest (SD) 75 (70–80) 78 (70–85)
Proteinuria, n (%)
Yes 0 (0) 0 (0)
No 28 (100) 7 (100)
Prior history of hypertension or preeclampsia, n (%)
Yes 0 (0) 0 (0)
No 28 (100) 20 (100)
Pregnancy
Gestational age at delivery, wk
þ d (SD [d])
39 þ 4 (9) 39 þ 1 (9)
Term, n (%)
A term 28 (100) 20 (100)
Preterm 0 (0) 0 (0)
Mode of delivery, n (%)
Cesarean section 16 (63.2) 12 (63.2)
Vaginal delivery 12 (36.8) 12 (36.8)
Twin or triplet, n (%)
Yes 0 (0) 0 (0)
No 28 (100) 20 (100)
Fetal n ¼ 28 n ¼ 20
Sex of child, n (%)
Male 12 (42.9) 13 (65)
Female 16 (57.1) 7 (35.0)
Birth weight, g (SD) 3,597 (435) 3,563 (564)
Small for gestational age, n (%)
Yes 2 (7.1) 1 (5)
No 26 (92.9) 19 (95)
Placenta weight, g (SD) 638 (140) 611 (119)
Note: NC ¼ naturally conceived.
a P< .05 compared with uncomplicated NC pregnancies.
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